Gliclazide

Gliclazide

Clinical data
ATC code	A10BB09 (WHO)
Identifiers
IUPAC name 3-(7-azabicyclo[3.3.0]oct-7-yl)- 1-(4-methylphenyl)sulfonyl-urea
CAS Number	21187-98-4
PubChem CID	3475
DrugBank	APRD00460
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H21N3O3S
Molar mass	323.412 g/mol

WikiDoc Resources for Gliclazide
Articles
Most recent articles on Gliclazide Most cited articles on Gliclazide Review articles on Gliclazide Articles on Gliclazide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Gliclazide Images of Gliclazide Photos of Gliclazide Podcasts & MP3s on Gliclazide Videos on Gliclazide
Evidence Based Medicine
Cochrane Collaboration on Gliclazide Bandolier on Gliclazide TRIP on Gliclazide
Clinical Trials
Ongoing Trials on Gliclazide at Clinical Trials.gov Trial results on Gliclazide Clinical Trials on Gliclazide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Gliclazide NICE Guidance on Gliclazide NHS PRODIGY Guidance FDA on Gliclazide CDC on Gliclazide
Books
Books on Gliclazide
News
Gliclazide in the news Be alerted to news on Gliclazide News trends on Gliclazide
Commentary
Blogs on Gliclazide
Definitions
Definitions of Gliclazide
Patient Resources / Community
Patient resources on Gliclazide Discussion groups on Gliclazide Patient Handouts on Gliclazide Directions to Hospitals Treating Gliclazide Risk calculators and risk factors for Gliclazide
Healthcare Provider Resources
Symptoms of Gliclazide Causes & Risk Factors for Gliclazide Diagnostic studies for Gliclazide Treatment of Gliclazide
Continuing Medical Education (CME)
CME Programs on Gliclazide
International
Gliclazide en Espanol Gliclazide en Francais
Business
Gliclazide in the Marketplace Patents on Gliclazide
Experimental / Informatics
List of terms related to Gliclazide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®. DIAMICRON MR is also distributed as: Diabeton MR, Diamicron 30mg, Diamicron LM 30mg, Diamicron MR 30 mg, Diamicron Uno 30mg, Dianormax MR, Diaprel MR and Uni Diamicron.

Form and Composition:

Each tablet contains 80 mg of gliclazide.

Not marketed in the United States.

Indication:

Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.

Dosage:

40 to 240 mg depending on response, once or twice daily before food, no more that 160 mg at a time.

Properties:

Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. Glycemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.

Contraindications:

type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.

Interactions:

Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, β-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, β-blockers, possibly ACE inhibitors.

Adverse effects:

Hypoglycemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).

Overdosage:

Possible severe hypoglycemia requiring urgent IV glucose and monitoring.

External links

• Official site for Diamicron MR

Template:WikiDoc Sources